Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013

Abstract

The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called "incretin defect" in patients with T2DM.

Keywords: antidiabetic drugs; dipeptidyl peptidase 4 inhibitors; glucagon-like peptide-1 receptor agonists; incretin analogs; type 2 diabetes therapy; 降糖药物，二肽基肽酶4抑制剂，胰高血糖素样肽-1受体激动剂，肠促胰岛素类似物，2型糖尿病治疗.